文献速递临床免疫分子诊断质量管理与危急值

ISG15作为乳腺癌新型血清生物标志物:诊断与预后意义、临床实验室应用及多标志物整合策略

ISG15 as a novel serum biomarker for breast Cancer: Diagnostic and prognostic significance, clinical laboratory applications, and multi-biomarker integration strategies.
PubMed 文献 · Clin Chim Acta · 2026-04-20

本文综述血清ISG15在乳腺癌诊断与预后中的价值。现有血清标志物如CA15-3、癌胚抗原及循环HER2胞外域早期敏感性差、单独检测特异性不完整。ISG15为干扰素刺激基因15编码的泛素样修饰蛋白,免疫激活时释放入血,可反映肿瘤相关免疫信号与疾病进展。直接乳腺癌血清证据不丰富,多数证据来自其他癌种或组织研究。分析研究证实ISG15可在血清中检测,但分析前变量、检测平台、分析灵敏度及研究间异质性对测定浓度影响显著。非恶性感染和炎症性疾病也可致ISG15升高。现有证据提示ISG15可能无法替代已知肿瘤标志物,但纳入多重标志物和风险算法时可能具有附加临床价值。

要点

  • 血清ISG15可检测,但分析前变量与检测平台显著影响测定浓度
  • 非恶性感染和炎症性疾病也可升高ISG15,解读需考虑
  • ISG15可能无法替代CA15-3等已知标志物,多标志物整合或具附加价值

核心结论

  • 血清ISG15是生物学可行且可分析检测的候选生物标志物,符合转化临床化学目标。
  • 其临床实施需要检测方法协调、外部验证及在现有实验室检测基础上的增量验证。

研究设计与样本

  • 本文为综述,批判性评估血清ISG15在乳腺癌诊断与预后中的相关性,置于临床化学与实验室医学背景中。
  • 文中指出直接乳腺癌血清证据不丰富,多数证据外推自其他癌种或基于组织的研究。

主要发现

  • 分析研究证实ISG15可在血清中检测,但分析前变量、检测平台、分析灵敏度及研究间异质性对测定浓度有强影响。
  • ISG15在非恶性感染和炎症性疾病中也可升高,临床解读时应予考虑。
  • 现有证据表明ISG15可能无法替代已知肿瘤标志物,但纳入多重标志物和风险算法时可能具有附加临床价值。

关键数值与推荐

  • 现有血清标志物如CA15-3、癌胚抗原及循环HER2胞外域在疾病早期敏感性差,单独检测特异性不完整。
  • ISG15临床实验室实践需要标准化检测、明确决策限、严格质量管理及跨多样患者群的前瞻性验证。

临床怎么用

  • 检验科智能体应关注ISG15检测的分析前变量、平台差异与分析灵敏度对结果的影响。
  • 解读ISG15结果时需排除非恶性感染和炎症性疾病的干扰。
  • ISG15不宜单独用于替代CA15-3等标志物,可考虑纳入多重标志物组合与风险算法。
  • 临床落地前需完成检测方法协调、外部验证及在现有检测基础上的增量验证。

局限性

  • 直接乳腺癌血清证据不丰富,多数证据外推自其他癌种或基于组织的研究。
  • 分析前变量、检测平台、分析灵敏度及研究间异质性对测定浓度影响显著。
  • ISG15在非恶性感染和炎症性疾病中也可升高,影响特异性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The clinical management of breast cancer depends on circulating biomarkers, which aid in the early detection of breast cancer, stratification of prognosis, and monitoring of therapy efficacy. However, existing serum markers, such as CA15-3, carcinoembryonic antigen, and circulating HER2 extracellular domain, have poor sensitivity in the early stages of the disease and incomplete specificity when used as individual tests. ISG15 (interferon stimulated gene 15) is a ubiquitin like modifier, which is released into the blood at the time of immune activation, has now become an easy-to-measurable circulating protein indicating tumor associated immune signaling and disease progression. This review critically assesses the relevance of serum ISG15 in the diagnosis and prognosis of breast cancer in the context of clinical chemistry and laboratory medicine. It should be mentioned that direct evidence of breast cancer serum is not abundant; most evidence is extrapolated to other forms of cancer or tissue-based research. Analytical studies have provided evidence that ISG15 can be detected in serum but have also emphasized that pre-analytical variables, assay platforms, analytical sensitivity, and inter-study heterogeneity have a strong effect on the measured concentrations. Moreover, ISG15 can be increased in non-malignant infections and inflammatory diseases, which should be considered when interpreting clinical measurements. Existing evidence indicates that ISG15 will probably not be able to replace well-known tumor markers but might have an additive clinical value when included in multiplexing biomarkers and risk algorithms. The enactment of ISG15 in clinical laboratory practices entails standardized assays, clearly defined decision limits, rigorous quality management, and prospective validation across diverse patient groups. Overall, serum ISG15 is a biologically feasible and analytically measurable candidate biomarker that meets the translational clinical chemistry objectives; however, its clinical implementation requires assay harmonization, outer validation, and incremental validation over the existing laboratory tests.

来源:Clin Chim Acta,查看原文。版权归原作者所有。

引用

  1. Rahman S, Al-Zharani M, Afzal M, et al. ISG15 as a novel serum biomarker for breast Cancer: Diagnostic and prognostic significance, clinical laboratory applications, and multi-biomarker integration strategies. Clin Chim Acta. 2026. PMID: 42019747. doi:10.1016/j.cca.2026.121019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。